Katrina Fischer, MD
Hematology/Oncology · Monterey
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 1
- 1 carrier
- Office
- 1
Offices
1 location · Monterey Bay Oncology A Medical Corporation · 14 clinicians in this group
Hospitals listed: Community Hospital of the Monterey Peninsula · Salinas Valley Health Medical Center. That is not proof they admit you there this week.
Plans that list them
1 plan · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Fischer’s office at (831) 375-4105 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A139123 · Current
Licensed to practise in California · since 2015 · expires 2027-07-31 · David Geffen School of Medicine at UCLA.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Community Hospital of the Monterey PeninsulaMonterey, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Montage HealthPatients rate it 4 of 5 · 84% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — CMS Medicare PSI 90: Patient safety and adverse events composite: 1.48 (1.22 to 1.74), Jul 2022 – Jun 2024Worse than the national rate — Postoperative acute kidney injury requiring dialysis rate: 3.12 (1.69 to 4.56) · 1,095 cases, Jul 2022 – Jun 2024Worse than the national rate — Postoperative respiratory failure rate: 19.24 (14.17 to 24.3) · 1,118 cases, Jul 2022 – Jun 2024Worse than the national rate — Postoperative sepsis rate: 9.62 (6.42 to 12.82) · 1,086 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.39, Oct 2024 – Sep 2025
- Salinas Valley Health Medical CenterSalinas, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of Salinas Valley Memorial Healthcare SystemPatients rate it 4 of 5 · 74% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.247, Oct 2024 – Sep 2025
See every measure and the patient survey for Community Hospital of the Monterey Peninsula
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 1 better, 5 the same, 1 worse of 7 measures. Readmissions: 0 better, 11 the same, 0 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.48 (1.22 to 1.74) | Worse | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 3.12 (1.69 to 4.56) · 1,095 cases | Worse | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 19.24 (14.17 to 24.3) · 1,118 cases | Worse | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 9.62 (6.42 to 12.82) · 1,086 cases | Worse | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.39 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.27 (0.39 to 2.16) · 1,873 cases | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 158.2 (110.65 to 205.75) · 140 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.3 · 74 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.8 · 135 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10 · 184 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.7 · 686 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 16.4 · 1,072 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8 · 328 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.8 · 3,300 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.29 (0.11 to 0.48) · 10,234 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.1 to 0.46) · 10,572 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.25 (1.47 to 5.04) · 2,617 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.37 (1.04 to 3.7) · 2,519 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.21 (0.75 to 3.66) · 744 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.61 (0.06 to 1.17) · 8,715 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5.2 · 156 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.28 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.799 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.732 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.7 · 152 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.6 · 625 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 6.3 · 193 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -3.2 · 749 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 7 · 1,074 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.5 · 850 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4 (2.7 to 5.8) · 224 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.5 (10.4 to 17.4) · 224 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 153 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.5 · 49 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14.2 (10.9 to 18.6) · 711 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (1 to 1.5) · 746 cases | No different | Jan 2024 – Dec 2024 |
What patients said (520 patients answered, 28% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 5 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 62% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 84% |
| Doctors "always" explained things so they could understand | 75% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 89% |
| Patients who gave a rating of "9" or "10" (high) | 82% |
| Staff "always" explained new medications | 79% |
| Nurses "always" explained things so they could understand | 79% |
| Nurses "always" listened carefully | 77% |
| Nurses "always" treated them with courtesy and respect | 89% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 84% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for Salinas Valley Health Medical Center
Behind the star rating — Deaths: 1 better, 7 the same, 0 worse of 8 measures. Safety: 1 better, 5 the same, 0 worse of 6 measures. Readmissions: 0 better, 9 the same, 1 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.247 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.32 (0.34 to 2.3) · 1,159 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.98 (0.68 to 1.29) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 198.42 (143.23 to 253.6) · 62 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.7 · 112 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.9 · 160 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.2 · 203 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.7 · 573 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 536 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 12.1 · 239 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.9 · 2,377 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.18 (0 to 0.37) · 7,593 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.24 (0.05 to 0.43) · 7,999 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.97 (1.83 to 6.1) · 1,428 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.7 (0.16 to 3.24) · 456 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.31 (0.87 to 3.76) · 1,325 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.78 (3.73 to 15.83) · 461 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.23 (1.52 to 8.95) · 453 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.65 (0.17 to 3.13) · 279 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.48 (0 to 1.11) · 6,011 cases | No different | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.487 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 1.082 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.432 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.373 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.5 · 197 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.2 · 491 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 18.2 · 224 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 8 · 660 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 569 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 485 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.9 (4.2 to 8.4) · 244 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11 (8.4 to 14.3) · 244 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 86 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.4 (9.9 to 17.9) · 197 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 489 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,383 patients answered, 16% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 79% |
| Nurses "always" communicated well | 81% |
| Doctors "always" communicated well | 78% |
| Staff "always" explained | 66% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 75% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 73% |
| Staff "always" explained new medications | 78% |
| Nurses "always" explained things so they could understand | 78% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 46% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 53% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
Original Medicare doctor bills
$2,500,139
Medicare paid this office $2,500,139 for 929 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection, daratumumab, 10 mg and hyaluronidase-fihj | 17 | $335,513 | None |
| Injection, pembrolizumab, 1 mg | 17 | $233,060 | None |
| Injection, denosumab, 1 mg | 82 | $173,485 | None |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 49 | $90,110 | None |
| Return visit (30+ min) | 549 | $85,315 | $108 |
See all 47 services
| Injection, daratumumab, 10 mg and hyaluronidase-fihj | 17 | $335,513 | None |
| Injection, pembrolizumab, 1 mg | 17 | $233,060 | None |
| Injection, denosumab, 1 mg | 82 | $173,485 | None |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 49 | $90,110 | None |
| Return visit (30+ min) | 549 | $85,315 | $108 |
| Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | 13 | $82,851 | None |
| Long return visit (40+ min) | 174 | $62,269 | $150 |
| Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg | 15 | $45,515 | $21 |
| Injection, infliximab, excludes biosimilar, 10 mg | 14 | $41,213 | None |
| Injection, ferric carboxymaltose, 1 mg | 45 | $35,812 | None |
| Administration of chemotherapy into vein, 1 hour or less | 116 | $31,251 | $117 |
| Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram | 16 | $13,805 | None |
| Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | 11 | $13,592 | None |
| Short return visit (20+ min) | 112 | $11,491 | $78 |
| Insertion of needle into vein for collection of blood sample | 391 | $9,532 | $9 |
| New patient visit (60+ min) | 51 | $9,139 | $179 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 90 | $8,469 | $56 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 88 | $7,954 | $25 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 335 | $7,427 | $8 |
| New patient visit (45+ min) | 50 | $7,067 | $141 |
| Injection of drug or substance under skin or into muscle | 195 | $5,420 | $12 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 21 | $4,599 | $65 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 227 | $4,563 | $13 |
| Administration of prolonged chemotherapy into vein | 14 | $3,238 | $116 |
| Administration of additional new drug or substance into vein, 1 hour or less | 22 | $2,869 | $57 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 26 | $2,455 | $65 |
| Administration of chemotherapy into vein, each additional hour | 46 | $2,431 | $25 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 18 | $1,846 | $97 |
| Telephone medical discussion with physician, 11-20 minutes | 16 | $1,244 | $73 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 26 | $1,163 | $21 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 19 | $1,115 | $18 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 26 | $1,113 | $17 |
| Injection of additional new drug or substance into vein | 32 | $764 | $14 |
| Irrigation of implanted venous access drug delivery device | 22 | $752 | $23 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 15 | $696 | $32 |
| Injection, zoledronic acid, 1 mg | 23 | $622 | None |
| Injection, fluorouracil, 500 mg | 13 | $539 | None |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 13 | $403 | None |
| Injection, oxaliplatin, 0.5 mg | 12 | $378 | None |
| Injection, palonosetron hcl, 25 mcg | 28 | $375 | None |
| Infusion into a vein for hydration, each additional hour | 14 | $218 | $11 |
| Injection, dexamethasone sodium phosphate, 1 mg | 61 | $123 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 42 | $66 | None |
| Urinalysis, manual test | 11 | $65 | $3 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 16 | $44 | None |
| Infusion, normal saline solution , 1000 cc | 12 | $29 | None |
| Unclassified drugs | 13 | $23 | None |
Who their Medicare patients are
929 Original Medicare patients in 2024. Average age 76 · Under 65 4% · 85 and older 17% · Women 64% · Also on Medicaid 14% · Health risk score 1.79. At or below the middle of the specialty; the typical hematology-oncology clinician is at 2.04.
Conditions among them: High blood pressure 70% · Cancer 40% · Coronary heart disease 32% · Chronic kidney disease 28% · Diabetes 27% · Atrial fibrillation 21% · COPD 20% · Depression 20% · Heart failure 18% · Dementia 7% · Stroke 7%.
The office billed $7,879,605, Medicare allowed $3,130,641 and paid $2,500,139; for 193,801 services of 135 kinds; $2,173,499 of it was for drugs given in the office and $326,640 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 929 | 193,801 | 76 | 1.79 | $7,879,605 | $2,500,139 |
| 2023 | 908 | 247,815 | 77 | 1.75 | $10,918,583 | $3,342,570 |
| 2022 | 537 | 67,936 | 76 | 1.60 | $3,025,198 | $932,179 |
| 2021 | 137 | 505 | 76 | 1.14 | $159,839 | $57,710 |
| 2020 | 92 | 7,157 | 75 | 1.33 | $336,410 | $115,037 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 55 services
| Injection, pembrolizumab, 1 mg | 22 | $549,876 | None |
| Injection, daratumumab, 10 mg and hyaluronidase-fihj | 16 | $545,209 | None |
| Injection, denosumab, 1 mg | 130 | $236,083 | None |
| Injection, omalizumab, 5 mg | 13 | $131,900 | None |
| Return visit (30+ min) | 502 | $102,323 | $106 |
| Long return visit (40+ min) | 148 | $73,606 | $148 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 29 | $58,795 | None |
| Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | 52 | $45,177 | $6 |
| Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg | 15 | $44,742 | $104 |
| Administration of chemotherapy into vein, 1 hour or less | 138 | $43,413 | $118 |
| Injection, infliximab, excludes biosimilar, 10 mg | 15 | $37,312 | None |
| Short return visit (20+ min) | 209 | $29,605 | $75 |
| Injection, ferric carboxymaltose, 1 mg | 28 | $27,094 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 119 | $14,089 | $57 |
| Insertion of needle into vein for collection of blood sample | 463 | $13,046 | $8 |
| New patient visit (45+ min) | 89 | $12,451 | $140 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 40 | $11,829 | $0 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 115 | $11,710 | $26 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 398 | $10,649 | $8 |
| Injection of drug or substance under skin or into muscle | 254 | $8,189 | $12 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 21 | $8,102 | $65 |
| New patient visit (60+ min) | 43 | $7,574 | $176 |
| Chronic care management services for two or more chronic conditions, first 30 minutes provided personally by health care professional, per calendar month | 37 | $5,833 | $68 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 13 | $5,752 | None |
| Administration of chemotherapy into vein, each additional hour | 59 | $4,295 | $25 |
| Administration of additional new drug or substance into vein, 1 hour or less | 34 | $4,115 | $59 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 32 | $3,817 | $67 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 18 | $2,921 | $101 |
| Drawing of blood for a medical problem | 13 | $2,511 | $81 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 25 | $1,820 | $20 |
| Telephone medical discussion with physician, 11-20 minutes | 20 | $1,688 | $77 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 17 | $1,399 | $18 |
| Injection of additional new drug or substance into vein | 45 | $1,353 | $14 |
| New patient visit (30+ min) | 15 | $1,322 | $88 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 23 | $1,291 | $30 |
| Blood test, comprehensive group of blood chemicals | 95 | $1,181 | $10 |
| Administration of additional new drug or substance into vein using push technique | 12 | $1,159 | $48 |
| Injection, zoledronic acid, 1 mg | 27 | $1,027 | None |
| Infusion into a vein for hydration, each additional hour | 27 | $815 | $11 |
| Infusion into a vein for hydration, 31-60 minutes | 14 | $712 | $30 |
| Injection, palonosetron hcl, 25 mcg | 40 | $640 | None |
| Injection, paclitaxel, 1 mg | 13 | $630 | None |
| Injection, fosaprepitant, 1 mg | 18 | $621 | None |
| Injection, oxaliplatin, 0.5 mg | 12 | $620 | None |
| Injection, fluorouracil, 500 mg | 11 | $615 | None |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 11 | $605 | None |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 17 | $321 | $18 |
| Injection, carboplatin, 50 mg | 11 | $286 | None |
| Ferritin (blood protein) level | 20 | $267 | $13 |
| Injection, dexamethasone sodium phosphate, 1 mg | 93 | $195 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 62 | $120 | None |
| Infusion, normal saline solution , 1000 cc | 26 | $93 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 24 | $76 | None |
| Lactate dehydrogenase (enzyme) level | 11 | $71 | $6 |
| Unclassified drugs | 14 | $15 | None |
2022: 33 services
| Return visit (30+ min) | 256 | $44,427 | $111 |
| Injection, denosumab, 1 mg | 34 | $39,106 | None |
| Long return visit (40+ min) | 148 | $36,905 | $150 |
| Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | 42 | $23,628 | $6 |
| Administration of chemotherapy into vein, 1 hour or less | 52 | $12,940 | $124 |
| Short return visit (20+ min) | 110 | $10,918 | $79 |
| New patient visit (60+ min) | 37 | $6,996 | $189 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 20 | $6,518 | $0 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 40 | $3,658 | $27 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 205 | $3,561 | $8 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 38 | $3,559 | $61 |
| New patient visit (45+ min) | 23 | $3,375 | $147 |
| Telephone medical discussion with physician, 21-30 minutes | 33 | $3,094 | $86 |
| Injection of drug or substance under skin or into muscle | 117 | $3,079 | $13 |
| Chronic care management services for two or more chronic conditions, first 30 minutes provided personally by health care professional, per calendar month | 19 | $3,079 | $73 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 11 | $2,829 | $69 |
| Administration of additional new drug or substance into vein, 1 hour or less | 16 | $2,538 | $60 |
| Blood test, comprehensive group of blood chemicals | 137 | $2,225 | $10 |
| Telephone medical discussion with physician, 11-20 minutes | 24 | $2,143 | $74 |
| Administration of chemotherapy into vein, each additional hour | 23 | $1,543 | $26 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 13 | $1,469 | $86 |
| Insertion of needle into vein for collection of blood sample | 219 | $1,426 | $3 |
| Vitamin d-3 level | 37 | $1,073 | $29 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 11 | $842 | $60 |
| Ferritin (blood protein) level | 45 | $668 | $13 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 18 | $605 | $21 |
| Blood test, thyroid stimulating hormone (tsh) | 16 | $543 | $16 |
| Injection of additional new drug or substance into vein | 17 | $516 | $14 |
| Injection, palonosetron hcl, 25 mcg | 16 | $295 | None |
| Lactate dehydrogenase (enzyme) level | 34 | $272 | $6 |
| Injection, dexamethasone sodium phosphate, 1 mg | 24 | $57 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 21 | $36 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 12 | $30 | None |
2021: 9 services
| Long return visit (40+ min) | 71 | $22,390 | $166 |
| Return visit (30+ min) | 52 | $7,805 | $120 |
| Short return visit (20+ min) | 49 | $7,285 | $82 |
| New patient visit (45+ min) | 42 | $5,643 | $134 |
| New patient visit (60+ min) | 23 | $4,707 | $205 |
| Telephone medical discussion with physician, 11-20 minutes | 46 | $4,530 | $70 |
| Telephone medical discussion with physician, 21-30 minutes | 21 | $3,134 | $101 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 19 | $843 | $30 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 11 | $278 | $21 |
2020: 5 services
| New patient visit (45+ min) | 26 | $3,885 | $149 |
| Long return visit (40+ min) | 14 | $2,504 | $139 |
| Short return visit (20+ min) | 21 | $2,181 | $73 |
| Administration of chemotherapy into vein, 1 hour or less | 13 | $2,119 | $151 |
| New patient visit (30+ min) | 13 | $1,343 | $103 |
Medicaid work
$25,467 in 2024
Medicaid paid $25,467 for 338 billed services this clinician did in 2024, up to 34 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 147 | $13,029 |
| Long return visit (40+ min) | 58 | $9,225 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 33 | $2,661 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 100 | $551 |
| 2024 | 338 | 4 | 34 | $25,467 |
| 2023 | 747 | 5 | 36 | $17,198 |
| 2022 | 284 | 4 | 27 | $390 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 277 | $10,792 |
| Long return visit (40+ min) | 76 | $5,634 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 265 | $739 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | 22 | $31 |
| COLLECTION VENOUS BLOOD VENIPUNCTURE | 107 | $2 |
2022
| Return visit (30+ min) | 91 | $253 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | 38 | $121 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 89 | $16 |
| COLLECTION VENOUS BLOOD VENIPUNCTURE | 66 | $0 |
Drugs they prescribed that Part D paid
$833,375
Pharmacies billed $833,375 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 4% of their Part D prescriptions (14 of 378) in 2024. At or below the middle of the specialty; the typical hematology-oncology clinician is at 5%.
279 generic and 99 brand-name prescriptions · $833,375 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Xarelto | 19 | $31,128 | $1,638 |
| Eliquis | 12 | $8,204 | $684 |
| Letrozole | 50 | $1,580 | $32 |
| Imatinib Mesylate | 12 | $884 | $74 |
| Hydroxyurea | 27 | $835 | $31 |
See all 7 drugs
| Xarelto | 19 | $31,128 | $1,638 |
| Eliquis | 12 | $8,204 | $684 |
| Letrozole | 50 | $1,580 | $32 |
| Imatinib Mesylate | 12 | $884 | $74 |
| Hydroxyurea | 27 | $835 | $31 |
| Dexamethasone | 21 | $270 | $13 |
| Prochlorperazine Maleate | 18 | $205 | $11 |
Year by year
| 2024 | 378 | 111 | 4% (14) | 26% | $833,375 |
| 2023 | 415 | 93 | 5% (22) | 27% | $1,122,276 |
| 2022 | 254 | 94 | None | None | $477,998 |
| 2021 | 440 | 88 | None | 15% | $389,357 |
| 2020 | 41 | 19 | None | None | $21,397 |
| 2017 | 20 | None | 0% (0) | 0% | $326 |
| 2016 | 18 | None | 0% (0) | 0% | $234 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 11 drugs
| Pomalyst | 18 | $338,116 | $18,784 |
| Imbruvica | 11 | $173,547 | $15,777 |
| Xarelto | 17 | $29,901 | $1,759 |
| Eliquis | 16 | $17,778 | $1,111 |
| Letrozole | 39 | $1,984 | $51 |
| Hydroxyurea | 32 | $1,545 | $48 |
| Imatinib Mesylate | 11 | $1,235 | $112 |
| Prochlorperazine Maleate | 18 | $442 | $25 |
| Anastrozole | 12 | $360 | $30 |
| Dexamethasone | 18 | $298 | $17 |
| Prednisone | 14 | $248 | $18 |
2022: 6 drugs
| Eliquis | 13 | $15,113 | $1,163 |
| Anastrozole | 60 | $2,087 | $35 |
| Hydroxyurea | 15 | $435 | $29 |
| Prochlorperazine Maleate | 18 | $278 | $15 |
| Gabapentin | 23 | $257 | $11 |
| Prednisone | 11 | $71 | $6 |
2021: 10 drugs
| Eliquis | 17 | $14,093 | $829 |
| Abiraterone Acetate | 16 | $10,886 | $680 |
| Anastrozole | 77 | $3,070 | $40 |
| Prochlorperazine Maleate | 76 | $1,062 | $14 |
| Dexamethasone | 28 | $900 | $32 |
| Ondansetron | 25 | $527 | $21 |
| Acyclovir | 23 | $409 | $18 |
| Lidocaine-Prilocaine | 12 | $319 | $27 |
| Hydroxyurea | 15 | $185 | $12 |
| Prednisone | 19 | $159 | $8 |
Money from drug and device companies
$1,130 in 2025
| 2025 | 4 | 15 | None | $1,130 |
| 2024 | 3 | 14 | None | $1,066 |
| 2023 | 4 | 6 | None | $442 |
| 2022 | 3 | 3 | None | $72 |
| 2021 | 2 | 5 | None | $157 |
| 2019 | 1 | 1 | None | $121 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Novartis Pharmaceuticals | Kisqali | $1,000 | 12 payments
|
| AstraZeneca Pharmaceuticals LP | Imfinzi | $68 | 1 payment
|
| Adaptive Biotechnologies | Clonoseq | $32 | 1 payment
|
| Novocure | Optune Gio | $30 | 1 payment
|
See all 15 published payments
| Novartis Pharmaceuticals | Long term medical supply or device loan · 2025-12-30 | Kisqali | $83 |
| Novartis Pharmaceuticals | Long term medical supply or device loan · 2025-11-26 | Kisqali | $83 |
| Novartis Pharmaceuticals | Long term medical supply or device loan · 2025-10-23 | Kisqali | $83 |
| Novartis Pharmaceuticals | Long term medical supply or device loan · 2025-09-19 | Kisqali | $83 |
| Novartis Pharmaceuticals | Long term medical supply or device loan · 2025-08-21 | Kisqali | $83 |
| AstraZeneca Pharmaceuticals LP | Education · 2025-07-29 | Imfinzi | $68 |
| Novartis Pharmaceuticals | Long term medical supply or device loan · 2025-07-25 | Kisqali | $83 |
| Novartis Pharmaceuticals | Long term medical supply or device loan · 2025-06-12 | Kisqali | $83 |
| Novartis Pharmaceuticals | Long term medical supply or device loan · 2025-05-15 | Kisqali | $83 |
| Novartis Pharmaceuticals | Long term medical supply or device loan · 2025-04-24 | Kisqali | $83 |
| Novartis Pharmaceuticals | Long term medical supply or device loan · 2025-03-26 | Kisqali | $83 |
| Adaptive Biotechnologies | Meals · 2025-03-06 | Clonoseq | $32 |
| Novartis Pharmaceuticals | Long term medical supply or device loan · 2025-02-21 | Kisqali | $83 |
| Novartis Pharmaceuticals | Long term medical supply or device loan · 2025-01-23 | Kisqali | $83 |
| Novocure | Meals · 2025-01-23 | Optune Gio | $30 |
See earlier years (2024, 2023, 2022, 2021, 2019)
2024: $1,066
| Novartis Pharmaceuticals | Kisqali | $1,016 | 12 payments
|
| GlaxoSmithKline | Nucala | $33 | 1 payment
|
| Tempus AI | None | $16 | 1 payment
|
2023: $442
| Novartis Pharmaceuticals | None | $299 | 3 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $98 | 1 payment
|
| CTI BioPharma | Vonjo | $27 | 1 payment
|
| Novocure | Optune Lua (Novottf-200t) | $18 | 1 payment
|
2022: $72
| Pfizer | Ibrance | $32 | 1 payment
|
| Incyte | Jakafi | $27 | 1 payment
|
| GlaxoSmithKline | Zejula | $13 | 1 payment
|
2021: $157
| GlaxoSmithKline | Zejula | $136 | 4 payments
|
| Myriad Genetic Laboratories | Myrisk | $21 | 1 payment
|
2019: $121
| Genentech USA | Alecensa | $121 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 96.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1477972388
- Licence
- CA A139123California A139123: Current · expires 2027-07-31
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RH0003X (207RH0003X)
- Mailing address
- 325 Distel Cir, Los Altos, CA, 94022
- NPI first listed
- 2014-04-08
- NPI last updated
- 2020-08-17
- NPI record certified
- 2020-08-17
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 300 Pasteur Dr, Stanford, CA, 94305